Pipeline

Carna has leveraged its expertise in kinase biology to establish an innovative product pipeline focused on cancer and immune disorders. We achieve success by coupling our deep understanding of cell signaling with our extensive drug discovery expertise to generate therapeutics that inhibit kinases and provide new treatment options for patients with high unmet medical needs.

Compound   Development Phase
NCB-0846 Indication:Cancer
Target:wnt-signal
      Preclinical
NCB-0594 Indication:Cancer
Target:wnt-signal
    Candidate
Selection
 
AS-871 Indication:Autoimmune Diseases
Target:BTK
      Preclinical
Small
Molecule
Indication:Leukemic Stem Cell, Immuno-Oncology
Target:TGFβ signaling
  Lead
Optimization
   
Small
Molecule
Indication:Autoimmune Diseases
Target:Kinase
Lead
Generation
     
Small
Molecule
Indication:Malaria
Target:N/A
  Lead
Optimization
   
Small
Molecule
Neurodegenerative disease
Target:Kinase
  Lead
Optimization
   
Small
Molecule
Indication:Anemia
Target:Kinase
  Lead
Optimization
   
Page Top